We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
-2.18%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$199M
AUM Growth
-$12.8M
Cap. Flow
+$1.14M
Cap. Flow %
0.57%
Top 10 Hldgs %
99.55%
Holding
11
New
–
Increased
2
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$4.65M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$3.3M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$6.46M
2
ALGS icon
Aligos Therapeutics
ALGS
+$181K
3
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$172K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$112M 56.18%
881,458
+28,750
+3% +$3.3M
PCVX icon
2
Vaxcyte
PCVX
$8.81B
$18.1M 9.12%
832,166
-279,319
-25% -$6.46M
RLYB icon
3
Rallybio
RLYB
$87M
$17.1M 8.64%
283,914
– –
INZY
4
DELISTED
Inozyme Pharma
INZY
$12.7M 6.39%
2,661,154
+1,070,000
+67% +$4.65M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.3B
$12.1M 6.11%
569,041
– –
AKUS
6
DELISTED
Akouos Inc
AKUS
$8.41M 4.24%
1,794,088
– –
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$8.41M 4.24%
772,285
– –
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$3.89M 1.96%
1,560,982
-37,395
-2% -$172K
BOLT icon
9
Bolt Biotherapeutics
BOLT
$7.65M
$3.86M 1.94%
94,573
– –
VIGL
10
DELISTED
Vigil Neuroscience
VIGL
$1.45M 0.73%
560,595
– –
ALGS icon
11
Aligos Therapeutics
ALGS
$45.5M
$899K 0.45%
29,729
-5,333
-15% -$181K

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q2 2022 Portfolio in Review

As of Q2 2022, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $199M, down 6.1% from $211M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 0%. Pivotal bioVenture Partners Investment Advisor opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pivotal bioVenture Partners Investment Advisor added most to Inozyme Pharma in Q2 2022, an estimated $4.65M increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q2 2022 reduction was Vaxcyte, cutting an estimated $6.46M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $199M portfolio in Q2 2022.
  • Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 0 in Q2 2022.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 6.1% quarter-over-quarter to $199M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2022, filed 12 Aug 2022.